Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05642611 · ClinicalTrials.gov registry record · Phase 3

Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy

A Phase 3 study of Malignant Solid Neoplasm, sponsored by SWOG Cancer Research Network.

Recruiting
Registry status
Phase 3
Development phase
777
Enrollment target
20
Study locations

NCT05642611: Recruiting Phase 3 study of Malignant Solid Neoplasm, sponsored by SWOG Cancer Research Network.

NCT05642611 is a Phase 3 study of Malignant Solid Neoplasm that is actively recruiting participants, run by SWOG Cancer Research Network. The registered enrollment target is 777 participants, below the 1,136-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (32% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05642611, a Phase 3 study of Malignant Solid Neoplasm, is actively recruiting participants, sponsored by SWOG Cancer Research Network.

RECRUITING
Registry status
Phase 3
Development phase
777 participants
Enrollment target
20
Study locations

Study Summary

This phase III trial compares the effect of 3 study approaches in preventing chemotherapy-induced peripheral neuropathy: 1) cryocompression, 2) continuous compression, and 3) low cyclic compression. Taxane chemotherapy drugs, such as paclitaxel or docetaxel, can cause a nerve disorder called peripheral neuropathy, which can cause numbness, tingling, or pain in the arms and legs. The 3 study approaches will use a device, called the Paxman Limb Cryocompression System, made of wraps that cool and/or compress the arms and legs. This study may help researchers determine if any of the study approaches are able to prevent taxane chemotherapy from causing peripheral neuropathy.

Primary Outcome

Defined as an absolute increase of 8 or more points over baseline in the CIPN-20 sensory neuropathy subscale score. Analysis will be conducted multivariable logistic regression, adjusting for the baseline score and the stratification factor as covariates.

Conditions Studied

Interventions

  • PROCEDURE Biospecimen Collection
  • OTHER Quality-of-Life Assessment
  • PROCEDURE Cryocompression Therapy
  • PROCEDURE Pneumatic Compression Therapy

Study Locations (20)

Kansas

  • University of Kansas Cancer Center - Kansas City
  • University of Kansas Hospital-Indian Creek Campus - Overland Park
  • University of Kansas Hospital-Westwood Cancer Center - Westwood

Michigan

  • Henry Ford Macomb Hospital-Clinton Township - Clinton Township
  • Henry Ford Hospital - Detroit
  • Corewell Health Grand Rapids Hospitals - Butterworth Hospital - Grand Rapids

North Carolina

  • CaroMont Regional Medical Center - Gastonia
  • Cone Health Cancer Center - Greensboro
  • Margaret R Pardee Memorial Hospital - Hendersonville

New Jersey

  • The Valley Hospital - Luckow Pavilion - Paramus
  • Valley Health System Ridgewood Campus - Ridgewood

New York

  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center - New York
  • State University of New York Upstate Medical University - Syracuse

Alabama

  • University of Alabama at Birmingham Cancer Center - Birmingham

California

  • Contra Costa Regional Medical Center - Martinez

Georgia

  • Emory University Hospital/Winship Cancer Institute - Atlanta

Trial Details

FieldValue
Enrollment Target 777 participants
Start Date 2023-06-06
Est. Completion 2031-08-30
Phase Phase 3
SWOG Cancer Research Network

270 total trials

What NCT05642611 shows while recruiting

NCT05642611 is an interventional study that assigns participants to a tested intervention. The registered 777 participants enrollment target is mid-sized for trials with a published cap, below the 1,136-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (32% lower).

The record links to 1 condition, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.

NCT05642611 names 20 study sites across 12 states, led by Kansas, Michigan, North Carolina.

Frequently Asked Questions

What is clinical trial NCT05642611 about?

NCT05642611 is a clinical study titled "Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy". This phase III trial compares the effect of 3 study approaches in preventing chemotherapy-induced peripheral neuropathy: 1) cryocompression, 2) continuous compression, and 3) low cyclic compression. Taxane chemotherapy drugs, such as paclitaxel or docetaxel, can cause a nerve disorder called periphe...

What is the current status of trial NCT05642611?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 777 participants. The study started on 2023-06-06. Estimated completion is 2031-08-30.

What conditions does trial NCT05642611 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm.

What interventions are being tested in trial NCT05642611?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Quality-of-Life Assessment (OTHER), Cryocompression Therapy (PROCEDURE), Pneumatic Compression Therapy (PROCEDURE).

Who is sponsoring clinical trial NCT05642611?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05642611 being conducted?

This trial has 20 study locations across Alabama, California, Georgia, Hawaii, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05642611's enrollment target sits among peer trials

777 21st of 176 higher than 156 of 176 other Malignant Solid Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06841679 · 778 participants · Phase 2

    Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

  • NCT06145763 · 776 participants · NA

    A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking, IndigeQuit Trial

  • NCT03460769 · 775 participants

    Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)

  • NCT05046613 · 780 participants

    Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05642611, the US trial registry maintained by the National Library of Medicine. NCT05642611 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.